Brought to you by 
Lilly & Neurocrine develop CRF for Alzheimer's & obesity
06 Apr 2001
Executive Summary
Eli Lilly and Neurocrine Biosciences will collaborate to develop treatments for dementia associated with Alzheimer's disease, and obesity. The diseases are related through suppressed levels of corticotropin releasing factor.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly & Neurocrine develop CRF for Alzheimer's & obesity
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice